Attenuated acute cardiac rejection in NOS2 -/- recipients correlates with reduced apoptosis

J Koglin1, D J Granville, T Glysing-Jensen

  • 1Cardiovascular Biology Laboratory, Harvard School of Public Health, Boston, Mass. 02115, USA.

Circulation
|February 17, 1999
PubMed
Abstract

Insights

Nitric oxide synthase 2 (NOS2) promotes acute cardiac allograft rejection by inducing apoptosis. NOS2 knockout mice show reduced graft apoptosis and improved outcomes, suggesting NOS2 is a therapeutic target.

Area of Science:

  • Immunology
  • Molecular Biology
  • Transplantation Science

Background:

  • Mechanisms of graft failure in acute cardiac rejection are not fully understood.
  • The role of nitric oxide synthase 2 (NOS2) in promoting apoptosis during rejection is unclear.

Purpose of the Study:

  • To investigate if NOS2-mediated pathways contribute to graft failure by inducing apoptosis.
  • To determine the role of NOS2 in acute cardiac allograft rejection using a knockout mouse model.

Main Methods:

  • Utilized a heterotopic cardiac transplant model in mice with targeted gene deletion of NOS2 (NOS2-/-) and wild-type controls (NOS2+/+).
  • Assessed apoptosis using five distinct indexes, including TUNEL staining, DNA fragmentation, caspase activity, and gene expression analysis.
  • Analyzed intragraft transcript levels of apoptosis-related genes, including p53, Bcl-2, Bax, and Bcl-Xl.

Main Results:

  • NOS2-/- recipients exhibited significantly reduced apoptotic activity in cardiac allografts compared to NOS2+/+ controls.
  • Key apoptosis markers (TUNEL, DNA fragmentation, caspase-1/-3 levels, caspase-3 activity) were significantly lower in grafts from NOS2-/- mice.
  • Improved histological outcomes (lower rejection scores) correlated with reduced apoptosis in grafts from NOS2-/- recipients.
  • NOS2 deficiency led to lower p53 transcript levels and an altered Bcl-2/Bax and Bcl-Xl balance, favoring apoptosis resistance.

Conclusions:

  • NOS2-mediated pathways significantly contribute to acute cardiac allograft rejection by inducing apoptotic cell death.
  • In the presence of NOS2, p53 may regulate apoptosis by modulating Bax, Bcl-2, and Bcl-Xl expression, thereby activating cell death pathways in rejecting hearts.

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...